Distinct Patient, Tumour, Treatment Characteristics and a Different Pattern and Risk of Survival Events Over Time Between Young BRCA1/2 Carriers By Ogkologos - March 10, 2025 631 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a global cohort of patients harbouring germline pathogenic/likely pathogenic variants in BRCA1 or BRCA2 Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Lessons from the green: How sports psychology helped a top golf... March 16, 2023 Virtual Reality Found to Benefit Cancer Patients’ Mental Health October 15, 2021 Happy 29th Birthday OncoLink! March 7, 2023 Cetuximab Outperforms Durvalumab for Head and Neck Cancer When Cisplatin Isn’t... December 19, 2024 Load more HOT NEWS Pruebas genéticas para el cáncer en familias: Preguntas y respuestas con... 5 Kids Battling Sickle Cell And Cancer Model Their Dream Jobs... Survivor’s Lucky Chance Encounter with Her Old Surgeon Leads to an... Reducing the Cancer Burden: Future Directions for NCI’s Cancer Control Research